Feedback (FDBK.L) Stock Price

Feedback Price

LSE·CLOSED
0.05
​
Market closed

Revenue at Feedback has contracted by 10.7% per year over the past 19 years to 885,623.00 GBP. Feedback's net margin stands at -826.2%, down from -563.5% several years earlier.

Feedback stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Feedback business model & stock analysis

Feedback PLC provides imaging tools for clinical decision makers, including TexRAD for medical research and clinical trial management, and Cadran for medical imaging decision support. The company offers Cadran Image Storage Management for image display, review, and enterprise archiving across clinical, non-clinical, and teaching environments. Subsidiaries such as Feedback Black Box Company Limited, Feedback Data GmbH, Brickshield Limited, Cambridge Computed Imaging Limited, TexRAD Limited, and Prostate Checker Ltd support its operations. The firm generates revenue through these products and services targeting medical practitioners, researchers, and pharmaceutical companies involved in cancer detection and treatment workflows. TexRAD is utilized by pharmaceutical companies for managing clinical trials and research, while Cadran and Cadran Image Storage Management are sold to healthcare providers and institutions requiring advanced imaging solutions. The company’s focus on imaging biomarkers for cancer detection attracts partnerships with medical research organizations and hospitals seeking to improve diagnostic accuracy and patient outcomes. Feedback Data GmbH and TexRAD Limited specifically contribute to the development and management of imaging techniques and workflow solutions for the medical sector. The business model centers on selling specialized imaging software and tools to healthcare institutions, pharmaceutical firms, and research organizations. Products like Cadran Image Storage Management are designed for enterprise-level archiving and image handling, appealing to large healthcare systems and academic institutions. TexRAD’s role in clinical trial management ensures recurring revenue streams from pharmaceutical clients who rely on its platform for trial execution and data management.

Frequently asked questions about Feedback

5 analysts currently rate the Feedback stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Feedback to generate revenue of 810,000.00 GBP and earnings per share of -0.00 GBP.

Converted at the current exchange rate, the Feedback share trades at 0.06 EUR (0.05 GBP).

The Feedback share (FDBK.L) is listed on 3 stock exchanges, including: London (FDBK.L), Frankfurt (GZM.F).

The expected revenue of Feedback is 810,000.00 GBP. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Feedback is -71,003.80 GBP. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Feedback is currently -31.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Feedback stock.

The price-to-sales ratio (P/S) of Feedback is currently 2.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Feedback stock.

The Eulerpool Quality Score for Feedback is 6/10.

The ISIN of Feedback is GB00BJN59X09. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Feedback is A0B6UQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Feedback is FDBK.L. The ticker symbol is used to trade Feedback shares on the stock exchange.

Fair ValueTerminal
0.04 GBP
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue per Employee
35,424.92 GBP
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website fbk.com
Currency
GBP
Initial public offering
Jan 8, 1986
ISIN
GB00BJN59X09
Cusip
G33572101
Sedol
0334055
Market capitalization
1.46 M GBPMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-31.47
P/Ee 2026
—
P/Ee 2027
-30.53
P/Ee 2027
—
P/S
P/Se
2.76
EV/EBIT
—
P/B Ratio
0.24
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-118.70 %
Last updated Nov 3, 2026, 3:48 AM

Feedback Ticker

FRANKFURT · GZM.FLONDON · FDBK.LLONDON STOCK EXCHANGE · FDBK.L

All fundamentals and in-depth analysis of Feedback

Our stock analysis for Feedback stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Feedback. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.